MarkWide Research

Sale!

Global Gene Therapy Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: August, 2022
No of Pages: 153
Delivery Format: PDF + Excel

$2,950.00

The global Gene Therapy Market Size was valued at $6.0 billion in 2020 and is projected to reach $46.5 billion by 2030, growing at a CAGR of 22.8% from 2021 to 2030. Gene is a functional hereditary unit of life that carries a set of instructions for a particular function. Gene therapy is the advanced treatment applied for cancer, chronic disease, infectious disease, and blood disorders. Gene therapy involves the partial or full replacement of defective genes in a patient’s body with healthy ones to treat or prevent disease proliferation. There are two types of gene therapy based on the location of the target gene on a chromosome including somatic gene therapy & germline gene therapy. It can be applied for the treatment of several diseases, such as Parkinson’s, hemophilia, cystic fibrosis, Alzheimer’s, brain tumors, cancer, AIDS, SCID, and others. The transgene is transferred into the host cell by biological vectors, such as the virus, liposome, and plasmids. These vectors are further categorized as viral vectors & non-viral vectors. The viral vector consists of retrovirus, lentivirus, adenovirus, and adeno-associated vector. The non-viral vector includes liposomes, transposons, and plasmids. The physical methods are also available for gene transfer, such as electroporation, sonication, gene gun, and photoporation

The overall impact of COVID-19 remains negative on the gene therapy market, owing to a decline in the number of cancer patient visits to hospitals & clinics for gene therapy (ICI), which lead to a decline in demand for gene therapy products. For instance, according to the NCBI in 2020, around a 50% patient decrease is reported for cancer care in the U.S., and overall cancer therapies are declined by 50% during COVID-19 which leads to a decline in demand for gene therapy products in the market.

The key factor that drives the Gene Therapy Market Growth is an increase in the prevalence of chronic disorders such as cancer, rare disease genetic disorders, and others globally. In addition, an increase in government support, ethical acceptance of gene therapy for cancer treatment, and a rise in the prevalence of cancer fuel the growth of the market. Furthermore, an increase in healthcare expenditure, the presence of advanced healthcare infrastructure, availability of reimbursements provide Gene Therapy Market Opportunity. However, the high cost of gene therapies is expected to hamper the market growth to a certain extent during the forecast period.

The gene therapy market is segmented on the basis of vector type, gene type, application, and region. On the basis of vector type, it is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia viruses, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. By therapy type, the market is classified into ex vivo therapy and in vivo therapy. By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others.

By application, it is divided into oncological disorders, rare diseases, neurological disorders, and other diseases. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Global Gene Therapy Market Report Scope and Segmentation

ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

By Vector Type

Non Viral Vector segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

By vector type, the gene therapy market is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia viruses, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others.

The non-viral vector segment holds the largest Gene Therapy Market Size and is estimated to witness the highest CAGR during the forecast period. Owing to the rise in the incidence of cancer and other target diseases, the availability of reimbursements policies, and the increase in funding for gene therapy research are the key factors anticipating the growth of the market in upcoming years.


By Therapy

In Vivo Therapy segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

By therapy type, the market is classified into ex vivo therapy and in vivo therapy. The in vivo therapy segment held the largest market share in 2020. An increase in the adoption of in vivo gene therapies globally is expected to drive the growth of the market in the future


By Gene Type

Antigen segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. The antigen segment held the largest market share in 2020. An increase in the prevalence of autoimmune diseases, cancer, and R&D in antigen-based gene therapies are key factors anticipated to drive the growth of the market in upcoming years.

By Application

Oncological Disorder segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

By application, the Gene Therapy Industry is categorized into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and other diseases. The oncological disorders segment has highest Gene Therapy Market Share. The availability of many gene therapy products that can be used to treat cancer and a large patient population base is expected to drive the growth of the market in upcoming years.

By Region

2030

North America

Europe
Asia-pacific
Lamea

By region, the Gene Therapy Market Analysis is done across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest Gene Therapy Market Share in 2020. Owing to the rise in prevalence of chronic diseases, high and growing healthcare expenditure, presence of advanced healthcare infrastructure, availability of reimbursements, and the presence of major market players, the gene therapy market in North America is expected to grow during the forecast period.

The key players operating in the global Gene Therapy Industry include Novartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono Genentech, Shanghai Sunway Biotech Co., Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Amgen Inc., Astellas Therapeutics, Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Unique N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.

The gene therapy market is segmented into Vector Type, Therapy, Gene Type and Application.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene therapy market analysis from 2020 to 2030 to identify the prevailing gene therapy market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the gene therapy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global gene therapy market trends, key players, market segments, application areas, and market growth strategies.

Gene Therapy Market Report Highlights

SegmentsSub-segments
By Vector Type
  • Viral Vector
  • Non Viral Vector
By Therapy
  • In Vivo Therapy
  • Ex Vivo Therapy
By Gene Type
  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others
By Application
  • Oncological Disorders
  • Rare Diseases
  • Neurological Disorders
  • Other Diseases
By Region
  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Key Market PlayersNovartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono GeneTech, Shanghai Sunway Biotech Co. Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Astellas Therapeutics Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc., Merck and Co Inc., Dendron Corporation

Table of content

  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Viral Vector

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Non Viral Vector

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

  • CHAPTER 5: GENE THERAPY MARKET, BY THERAPY

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 In Vivo Therapy

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Ex Vivo Therapy

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

  • CHAPTER 6: GENE THERAPY MARKET, BY GENE TYPE

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Antigen

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Cytokine

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

    • 6.4 Tumor Suppressor

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market analysis by country

    • 6.5 Suicide

      • 6.5.1 Key market trends, growth factors and opportunities

      • 6.5.2 Market size and forecast, by region

      • 6.5.3 Market analysis by country

    • 6.6 Deficiency

      • 6.6.1 Key market trends, growth factors and opportunities

      • 6.6.2 Market size and forecast, by region

      • 6.6.3 Market analysis by country

    • 6.7 Growth factors

      • 6.7.1 Key market trends, growth factors and opportunities

      • 6.7.2 Market size and forecast, by region

      • 6.7.3 Market analysis by country

    • 6.8 Receptors

      • 6.8.1 Key market trends, growth factors and opportunities

      • 6.8.2 Market size and forecast, by region

      • 6.8.3 Market analysis by country

    • 6.9 Others

      • 6.9.1 Key market trends, growth factors and opportunities

      • 6.9.2 Market size and forecast, by region

      • 6.9.3 Market analysis by country

  • CHAPTER 7: GENE THERAPY MARKET, BY APPLICATION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 Oncological Disorders

      • 7.2.1 Key market trends, growth factors and opportunities

      • 7.2.2 Market size and forecast, by region

      • 7.2.3 Market analysis by country

    • 7.3 Rare Diseases

      • 7.3.1 Key market trends, growth factors and opportunities

      • 7.3.2 Market size and forecast, by region

      • 7.3.3 Market analysis by country

    • 7.4 Neurological Disorders

      • 7.4.1 Key market trends, growth factors and opportunities

      • 7.4.2 Market size and forecast, by region

      • 7.4.3 Market analysis by country

    • 7.5 Other Diseases

      • 7.5.1 Key market trends, growth factors and opportunities

      • 7.5.2 Market size and forecast, by region

      • 7.5.3 Market analysis by country

  • CHAPTER 8: GENE THERAPY MARKET, BY REGION

    • 8.1 Overview

      • 8.1.1 Market size and forecast

    • 8.2 North America

      • 8.2.1 Key trends and opportunities

      • 8.2.2 North America Market size and forecast, by Vector Type

      • 8.2.3 North America Market size and forecast, by Therapy

      • 8.2.4 North America Market size and forecast, by Gene Type

      • 8.2.5 North America Market size and forecast, by Application

      • 8.2.6 North America Market size and forecast, by country

        • 8.2.6.1 U.S.

          • 8.2.6.1.1 Market size and forecast, by Vector Type
          • 8.2.6.1.2 Market size and forecast, by Therapy
          • 8.2.6.1.3 Market size and forecast, by Gene Type
          • 8.2.6.1.4 Market size and forecast, by Application
        • 8.2.6.2 Canada

          • 8.2.6.2.1 Market size and forecast, by Vector Type
          • 8.2.6.2.2 Market size and forecast, by Therapy
          • 8.2.6.2.3 Market size and forecast, by Gene Type
          • 8.2.6.2.4 Market size and forecast, by Application
        • 8.2.6.3 Mexico

          • 8.2.6.3.1 Market size and forecast, by Vector Type
          • 8.2.6.3.2 Market size and forecast, by Therapy
          • 8.2.6.3.3 Market size and forecast, by Gene Type
          • 8.2.6.3.4 Market size and forecast, by Application
    • 8.3 Europe

      • 8.3.1 Key trends and opportunities

      • 8.3.2 Europe Market size and forecast, by Vector Type

      • 8.3.3 Europe Market size and forecast, by Therapy

      • 8.3.4 Europe Market size and forecast, by Gene Type

      • 8.3.5 Europe Market size and forecast, by Application

      • 8.3.6 Europe Market size and forecast, by country

        • 8.3.6.1 Germany

          • 8.3.6.1.1 Market size and forecast, by Vector Type
          • 8.3.6.1.2 Market size and forecast, by Therapy
          • 8.3.6.1.3 Market size and forecast, by Gene Type
          • 8.3.6.1.4 Market size and forecast, by Application
        • 8.3.6.2 France

          • 8.3.6.2.1 Market size and forecast, by Vector Type
          • 8.3.6.2.2 Market size and forecast, by Therapy
          • 8.3.6.2.3 Market size and forecast, by Gene Type
          • 8.3.6.2.4 Market size and forecast, by Application
        • 8.3.6.3 U.K.

          • 8.3.6.3.1 Market size and forecast, by Vector Type
          • 8.3.6.3.2 Market size and forecast, by Therapy
          • 8.3.6.3.3 Market size and forecast, by Gene Type
          • 8.3.6.3.4 Market size and forecast, by Application
        • 8.3.6.4 Italy

          • 8.3.6.4.1 Market size and forecast, by Vector Type
          • 8.3.6.4.2 Market size and forecast, by Therapy
          • 8.3.6.4.3 Market size and forecast, by Gene Type
          • 8.3.6.4.4 Market size and forecast, by Application
        • 8.3.6.5 Spain

          • 8.3.6.5.1 Market size and forecast, by Vector Type
          • 8.3.6.5.2 Market size and forecast, by Therapy
          • 8.3.6.5.3 Market size and forecast, by Gene Type
          • 8.3.6.5.4 Market size and forecast, by Application
        • 8.3.6.6 Rest of Europe

          • 8.3.6.6.1 Market size and forecast, by Vector Type
          • 8.3.6.6.2 Market size and forecast, by Therapy
          • 8.3.6.6.3 Market size and forecast, by Gene Type
          • 8.3.6.6.4 Market size and forecast, by Application
    • 8.4 Asia-Pacific

      • 8.4.1 Key trends and opportunities

      • 8.4.2 Asia-Pacific Market size and forecast, by Vector Type

      • 8.4.3 Asia-Pacific Market size and forecast, by Therapy

      • 8.4.4 Asia-Pacific Market size and forecast, by Gene Type

      • 8.4.5 Asia-Pacific Market size and forecast, by Application

      • 8.4.6 Asia-Pacific Market size and forecast, by country

        • 8.4.6.1 Japan

          • 8.4.6.1.1 Market size and forecast, by Vector Type
          • 8.4.6.1.2 Market size and forecast, by Therapy
          • 8.4.6.1.3 Market size and forecast, by Gene Type
          • 8.4.6.1.4 Market size and forecast, by Application
        • 8.4.6.2 China

          • 8.4.6.2.1 Market size and forecast, by Vector Type
          • 8.4.6.2.2 Market size and forecast, by Therapy
          • 8.4.6.2.3 Market size and forecast, by Gene Type
          • 8.4.6.2.4 Market size and forecast, by Application
        • 8.4.6.3 Australia

          • 8.4.6.3.1 Market size and forecast, by Vector Type
          • 8.4.6.3.2 Market size and forecast, by Therapy
          • 8.4.6.3.3 Market size and forecast, by Gene Type
          • 8.4.6.3.4 Market size and forecast, by Application
        • 8.4.6.4 India

          • 8.4.6.4.1 Market size and forecast, by Vector Type
          • 8.4.6.4.2 Market size and forecast, by Therapy
          • 8.4.6.4.3 Market size and forecast, by Gene Type
          • 8.4.6.4.4 Market size and forecast, by Application
        • 8.4.6.5 South Korea

          • 8.4.6.5.1 Market size and forecast, by Vector Type
          • 8.4.6.5.2 Market size and forecast, by Therapy
          • 8.4.6.5.3 Market size and forecast, by Gene Type
          • 8.4.6.5.4 Market size and forecast, by Application
        • 8.4.6.6 Rest Of Asia Pacific

          • 8.4.6.6.1 Market size and forecast, by Vector Type
          • 8.4.6.6.2 Market size and forecast, by Therapy
          • 8.4.6.6.3 Market size and forecast, by Gene Type
          • 8.4.6.6.4 Market size and forecast, by Application
    • 8.5 LAMEA

      • 8.5.1 Key trends and opportunities

      • 8.5.2 LAMEA Market size and forecast, by Vector Type

      • 8.5.3 LAMEA Market size and forecast, by Therapy

      • 8.5.4 LAMEA Market size and forecast, by Gene Type

      • 8.5.5 LAMEA Market size and forecast, by Application

      • 8.5.6 LAMEA Market size and forecast, by country

        • 8.5.6.1 Brazil

          • 8.5.6.1.1 Market size and forecast, by Vector Type
          • 8.5.6.1.2 Market size and forecast, by Therapy
          • 8.5.6.1.3 Market size and forecast, by Gene Type
          • 8.5.6.1.4 Market size and forecast, by Application
        • 8.5.6.2 Saudi Arabia

          • 8.5.6.2.1 Market size and forecast, by Vector Type
          • 8.5.6.2.2 Market size and forecast, by Therapy
          • 8.5.6.2.3 Market size and forecast, by Gene Type
          • 8.5.6.2.4 Market size and forecast, by Application
        • 8.5.6.3 South Africa

          • 8.5.6.3.1 Market size and forecast, by Vector Type
          • 8.5.6.3.2 Market size and forecast, by Therapy
          • 8.5.6.3.3 Market size and forecast, by Gene Type
          • 8.5.6.3.4 Market size and forecast, by Application
        • 8.5.6.4 Rest of LAMEA

          • 8.5.6.4.1 Market size and forecast, by Vector Type
          • 8.5.6.4.2 Market size and forecast, by Therapy
          • 8.5.6.4.3 Market size and forecast, by Gene Type
          • 8.5.6.4.4 Market size and forecast, by Application
  • CHAPTER 9: COMPANY LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top winning strategies

    • 9.3. Product Mapping of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Key developments

  • CHAPTER 10: COMPANY PROFILES

    • 10.1

      • 10.1.1 Company overview

      • 10.1.2 Company snapshot

      • 10.1.3 Operating business segments

      • 10.1.4 Product portfolio

      • 10.1.5 Business performance

      • 10.1.6 Key strategic moves and developments

Segmentation

By Vector Type
  • Viral Vector
  • Non Viral Vector
By Therapy
  • In Vivo Therapy
  • Ex Vivo Therapy
By Gene Type
  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others
By Application
  • Oncological Disorders
  • Rare Diseases
  • Neurological Disorders
  • Other Diseases

Major Companies

Novartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono GeneTech, Shanghai Sunway Biotech Co. Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Astellas Therapeutics Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc., Merck and Co Inc., Dendron Corporation

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF